ArticleCancer chemotherapy and pharmacology2025
Tumor response and thyroglobulin change in differentiated thyroid carcinoma treated with dabrafenib plus trametinib.
Article in Cancer chemotherapy and pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeIt has been reported that treatment response does not necessarily correlate with the change of thyroglobulin (Tg) during dabrafenib treatment in differentiated thyroid carcinoma (DTC). This study aimed to assess the association between the clinical response and Tg changes or inflammatory biomarkers in a real-world setting.
methodsThis retrospective multi center cohort study included 22 BRAF-mutated DTC patients treated with dabrafenib plus trametinib in three academic institutions.
resultsAll 22 patients harbored the BRAFV600E mutation. Twenty-one patients (95%) had papillary thyroid carcinoma histology, and one had poorly differentiated thyroid carcinoma histology. Among 16 patients without Tg antibody, 14 patients (88%) experienced an increase in their Tg levels one month after the initiation of dabrafenib plus trametinib. In addition, 11 patients (69%) experienced an increase in their Tg levels at the best clinical response. Among these 11 patients who had an increase in Tg level at the best clinical response, the numbers of patients who had partial response, stable disease, and progressive disease were 3, 8, and 0, respectively. Among the 19 patients in whom neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and lymphocyte-to-monocyte ratio were measured at baseline, no distinctive trends were identified between clinical response and change in those inflammatory biomarkers.
conclusionsTg changes during dabrafenib plus trametinib treatment may not be associated with clinical response to dabrafenib plus trametinib treatment. Further study is needed to clarify the association between Tg level or inflammatory biomarkers change and clinical response to dabrafenib plus trametinib treatment.
Indexed as
Identifiers
41026165What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.